Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen and Sanofi-Aventis Extend Alliance to Include Oncology Biomarker ID, Validation

NEW YORK, Feb. 7 (GenomeWeb News) - Ciphergen today said it will discover, validate, and identify biomarkers for a pre-clinical oncology drug efficacy study for Sanofi-Aventis.

 

Under the terms of the agreement, which is an extension of an earlier deal between the two companies, Ciphergen will analyze samples at one of its Biomarker Discovery Center laboratories using its suite of proteomic products, including PatternTrack Process and the ProteinChip System.

 

Financial terms were not disclosed.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.